Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies

NCT02240719 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT02240719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02240719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
April 9, 2018
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, recurrent adult diffuse large cell lymphoma, recurrent adult hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, refractory chronic lymphocytic leukemia